health insurance

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental...